These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 23342872)
1. [Management of hyperglycaemia in type 2 diabetes: a patient-centered approach]. Scheen AJ; Mathieu C Rev Med Liege; 2012 Dec; 67(12):623-31. PubMed ID: 23342872 [TBL] [Abstract][Full Text] [Related]
2. Patient-Centered Guidelines for Geriatric Diabetes Care: Potential Missed Opportunities to Avoid Harm. McCreedy EM; Kane RL; Gollust SE; Shippee ND; Clark KD J Am Board Fam Med; 2018; 31(2):192-200. PubMed ID: 29535235 [TBL] [Abstract][Full Text] [Related]
3. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit. Heald AH; Livingston M; Malipatil N; Becher M; Craig J; Stedman M; Fryer AA Diabetes Obes Metab; 2018 Jan; 20(1):185-194. PubMed ID: 28730750 [TBL] [Abstract][Full Text] [Related]
4. What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? Zenari L; Marangoni A Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():17-25. PubMed ID: 24034516 [TBL] [Abstract][Full Text] [Related]
5. The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia? Morales J; Assumpcao-Morales M Diabetes Obes Metab; 2018 Aug; 20(8):1809-1811. PubMed ID: 29658190 [TBL] [Abstract][Full Text] [Related]
6. Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017. Dennis JM; Henley WE; McGovern AP; Farmer AJ; Sattar N; Holman RR; Pearson ER; Hattersley AT; Shields BM; Jones AG; Diabetes Obes Metab; 2019 Jul; 21(7):1576-1584. PubMed ID: 30828962 [TBL] [Abstract][Full Text] [Related]
7. [Management of type 2 diabetes: new or previous agents, how to choose?]. Halimi S Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613 [TBL] [Abstract][Full Text] [Related]
8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668 [TBL] [Abstract][Full Text] [Related]
9. Early and intensive treatment: Glycaemic control in type 2 diabetes. Bailey CJ Diab Vasc Dis Res; 2006 Dec; 3(3):145-6. PubMed ID: 17160908 [No Abstract] [Full Text] [Related]
10. Analysis of English general practice level data linking medication levels, service activity and demography to levels of glycaemic control being achieved in type 2 diabetes to improve clinical practice and patient outcomes. Heald A; Davies M; Stedman M; Livingston M; Lunt M; Fryer A; Gadsby R BMJ Open; 2019 Sep; 9(9):e028278. PubMed ID: 31494602 [TBL] [Abstract][Full Text] [Related]
11. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Scheen AJ; Charbonnel B Diabetes Metab; 2014 Jun; 40(3):176-85. PubMed ID: 24792220 [TBL] [Abstract][Full Text] [Related]
12. Mismatch between ADA and AGS recommendations for glycated hemoglobin targets for older adults. Tasci I; Safer U; Naharci I; Sonmez A Prim Care Diabetes; 2018 Apr; 12(2):192-194. PubMed ID: 29396204 [TBL] [Abstract][Full Text] [Related]
13. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study. Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375 [TBL] [Abstract][Full Text] [Related]
14. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Inzucchi SE; Bergenstal RM; Buse JB; Diamant M; Ferrannini E; Nauck M; Peters AL; Tsapas A; Wender R; Matthews DR Diabetologia; 2012 Jun; 55(6):1577-96. PubMed ID: 22526604 [No Abstract] [Full Text] [Related]
15. Management of the patient with advanced complications, functional decline, and persistent hyperglycemia. Zettervall DK Consult Pharm; 2010 Jun; 25 Suppl B():5-10. PubMed ID: 20726377 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Khunti K; Gomes MB; Pocock S; Shestakova MV; Pintat S; Fenici P; Hammar N; Medina J Diabetes Obes Metab; 2018 Feb; 20(2):427-437. PubMed ID: 28834075 [TBL] [Abstract][Full Text] [Related]
17. Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say? Mathur S; Zammitt NN; Frier BM Drug Saf; 2015 Jan; 38(1):17-32. PubMed ID: 25481812 [TBL] [Abstract][Full Text] [Related]
18. Adherence to Guidelines for Inpatient Pharmacologic Management of Type 2 Diabetes in Adults and Glycemic Outcomes. Alkhiari R; Alzayer H; Aljazeeri J; Vanniyasingam T; Punthakee Z Can J Diabetes; 2018 Apr; 42(2):158-162. PubMed ID: 28662968 [TBL] [Abstract][Full Text] [Related]
19. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Hermans MP; Brotons C; Elisaf M; Michel G; Muls E; Nobels F; Eur J Prev Cardiol; 2013 Dec; 20(6):1095-105. PubMed ID: 22605788 [TBL] [Abstract][Full Text] [Related]
20. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Rosenstock J; Wilson C; Fleck P Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]